HC Wainwright Raises Praxis Price Target to $105 with Buy Rating

HC Wainwright Raises Praxis Price Target to $105 with Buy Rating

July 2, 2025

In a recent update, HC Wainwright has raised its price target for Praxis Precision Medicines (PRAX) to $105, maintaining a Buy rating. This move reflects the firm's optimistic outlook on the company's potential, driven by positive developments in its clinical programs and technical indicators [1].

HC Wainwright's analysts have reiterated their Buy rating, citing significant corporate events and promising clinical trial progress. However, they acknowledge that financial and valuation concerns remain significant, partially offsetting the positive outlook [1].

The price target of $105 represents a 102.35% upside from the current price of $51.89, suggesting a substantial potential increase in the stock's value. This rating is in line with the broader analyst consensus, which has been predominantly positive for PRAX over the past three months [1].

The recent update from HC Wainwright adds to the growing list of bullish analyst ratings for PRAX. In the current month, PRAX has received 14 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings, reflecting strong analyst consensus [1].

Despite the positive outlook, investors should remain cautious. The company's financial challenges and negative valuation metrics are notable concerns. However, the potential for clinical breakthroughs and positive technical indicators offer a glimmer of hope for future growth [1].

References:

[1] TipRanks. "PRAX Analyst Ratings Strong Buy 9 Ratings Strong Buy 9 Buy 0 Hold 0 Sell Based on 9 analysts giving stock ratings to Praxis Precision Medicines in the past 3 months." https://www.tipranks.com/stocks/prax/forecast